Table 3.

Genetic associations with Braak stage severity of neurofibrillary tau pathology

Marker	Gene	Definite PART		Probable PART		Alzheimer's disease
		B	P‐value	B	P‐value	B	P‐value
rs3752246	ABCA7	−0.013	0.850	−0.042	0.564	0.021	0.259
rs28834970	PTK2B	0.021	0.663	0.024	0.696	−0.001	0.951
rs11136000	CLU	−0.006	0.904	0.037	0.498	0.004	0.792
rs10948363	CD2AP	0.000	0.993	0.015	0.815	−0.019	0.267
rs983392	MS4A6A	−0.038	0.403	−0.086	0.127	−0.019	0.250
rs4938933	MS4A4A	−0.090	0.043 *	−0.084	0.115	−0.019	0.236
rs561655	PICALM	−0.013	0.763	−0.059	0.342	−0.009	0.603
rs3851179	PICALM	−0.023	0.602	−0.070	0.225	−0.003	0.860
rs7561528	BIN1	0.028	0.591	0.058	0.324	−0.002	0.879
rs6733839	BIN1	0.030	0.586	0.187	0.003 **	0.008	0.624
rs6656401	CR1	0.002	0.977	−0.019	0.804	0.028	0.164
H1	MAPT	−0.196	0.151	−0.122	0.430	−0.026	0.611
ε2	APOE	0.114	0.115	−0.108	0.286	−0.088	0.064
ε4	APOE	−0.001	0.995	0.209	0.008 *	0.056	0.001 **

Bold text indicates observed statistically significant associations: *P < 0.05 (uncorrected); **P < 0.0036 (Bonferroni correction of P < 0.05); Beta‐weights refer to incremental increase in Braak stage tau pathology with each additional genotype risk allele.